Type 2 Diabetes (T2D) Clinical Trials

• Male or female (sex assigned at birth, inclusive of all gender identities).

• Age 18-75 years (both inclusive) at the time of signing the informed consent.

• Diagnosed with type 2 diabetes greater than or equal to (≥) 180 days before screening.

• Stable daily dose(s) ≥ 90 days before screening of the following antidiabetic drug(s) or combination regimen(s) at effective or maximum tolerated dose as judged by the investigator:

⁃ metformin with or without sodium-glucose cotransporter-2 (SGLT2) inhibitor.

• HbA1c of 7.0-10.5 percent (%) (53-91 millimoles per mole (mmol/mol)) (both inclusive) as assessed by central laboratory at screening.

• Body mass index between 25.0 kg/m\^2 and 50.0 kg/m\^2 (both inclusive) at screening.